Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: Malaria Rapid Diagnostic Test
On June 13, 2007, the Food and Drug Administration
approved BinaxNOW® Malaria (Inverness Medical
Professional Diagnostics, Scarborough, Maine), the first malaria rapid diagnostic test (RDT) authorized for use in the United
States. Malaria RDTs, which detect circulating malaria-specific antigens, already are available in other countries and often are used
in settings where malaria microscopy is not available. In the United States, use of the RDT can decrease the amount of
time required to determine whether a patient is infected with malaria.
BinaxNOW® Malaria is approved for use by hospital and commercial laboratories, not by individual clinicians or
by patients themselves; however, the manufacturer is planning to seek a Clinical Laboratory Improvement Amendments
waiver for point-of-care use by clinicians. The RDT detects two different malaria antigens: HRP2, which is specific to
Plasmodium falciparum, and a malaria aldolase found in all four human species of malaria parasites. Although the test can identify
P. falciparum, it cannot distinguish between
Plasmodium vivax, Plasmodium ovale, or
Plasmodium malariae or detect mixed
infections. The manufacturer recommends that the laboratory maintain a supply of blood containing
P. falciparum for use as a positive control
(1).
Use of a malaria RDT does not eliminate the need to examine thick and thin blood smears for the presence of
malaria parasites. The RDT might not be able to detect infections with lower concentrations of malaria parasites, and data
are insufficient to determine the ability of this test to detect the two less common species of malaria parasite,
P. ovale and P. malariae. Therefore, all negative RDT results should be followed by microscopy to confirm the results and
accurately identify the species.
Although malaria treatment should be initiated after receipt of positive RDT results, these results also should be followed
by microscopy. In cases of nonfalciparum malaria, microscopy is needed to determine the species of malaria parasite. In
addition, because the result of the RDT is qualitative and not quantitative, it cannot be used to determine initial parasite density or
the parasitologic response to therapy. Therefore, serial microscopy is needed to quantify the proportion of red blood cells that
are infected, an important prognostic indicator that can be used to monitor response to therapy.
High-quality malaria microscopy is not always immediately available in every clinical setting. Although thick and thin
blood smears should be examined immediately, in some health-care settings, blood smears are either saved until a qualified person
is available to perform malaria microscopy or sent to commercial or reference laboratories. These practices have
resulted in delays in diagnosis and initiation of appropriate management. Clinicians should be aware that certain hospitals and
laboratories might offer RDT, which can aid the rapid diagnosis of malaria and result in prompt therapeutic intervention.
Reference
BinaxNOW® Malaria [package insert]. Scarborough, Maine: Inverness Medical Professional Diagnostics; 2007.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
